Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4066708 · 1 trial · 2 indications
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Part A Cohort 1: Single-Ascending Dose (SAD)- LY4066708 | EXPERIMENTAL | LY4066708 administered by intravenous (IV) injection |
| Part A Cohort 2: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 3A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by subcutaneous (SC) injection |
| Part A Cohort 3B: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by SC injection |
| Part A Cohort 4: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 5: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 5A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 6A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 6: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 1: Multiple-Ascending Dose (MAD)- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 2: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 3: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 4: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Placebo | PLACEBO_COMPARATOR | Placebo administered by IV injection |
| Placebo- Part A Cohort 3A and Part A Cohort 3B. | PLACEBO_COMPARATOR | Placebo administered by SC injection |
| Name | Type | Description |
|---|---|---|
| LY4066708 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Japanese Participants Only: To qualify as a participant of first-generation Japanese origin, the participant, the participant's ...
LY4066708 is an investigational small molecule being developed by Eli Lilly and Company for oncology. It is currently in Phase 1 clinical development, with a trial evaluating its safety, tolerability, and pharmacokinetics in healthy participants. The drug is not yet approved and remains under clinical investigation.
LY4066708 is being studied for use in oncology, specifically in the context of cancer. The ongoing Phase 1 trial enrolls healthy participants, and the study conditions include both healthy volunteers and cancer. Its potential therapeutic application is in cancer treatment, though it is still in early-stage clinical development.
LY4066708 is developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker LLY. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety, tolerability, and pharmacokinetics in healthy participants.
LY4066708 is in Phase 1 clinical development. The ongoing trial, NCT07046559, is a single- and multiple-ascending dose study in healthy participants. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and tolerability.
LY4066708 is being evaluated in one clinical trial, NCT07046559, titled 'A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants.' This Phase 1 trial is recruiting in the United Kingdom, with an enrollment of 104 participants, and is randomized, double-blind, and placebo-controlled.
LY4066708 is the sole name provided for this investigational drug. No alternative names or aliases have been associated with it in the available information. It is a distinct small molecule being developed by Eli Lilly and Company for oncology indications.